Trial Profile
Double-Blind, Randomized, Active-Controlled Comparison of the Immunogenicity and Safety of Flublok Quadrivalent Versus IIV4 in Healthy, Medically Stable Adults 18-49 Years of Age
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Dec 2020
Price :
$35
*
At a glance
- Drugs Influenza virus RIV4 vaccine-(FluBlok Quadrivalent) (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Protein Sciences Corporation
- 18 Nov 2020 According to a Sanofi media release, based on two phase studies (NCT02285998 and NCT02290509) the European Commission has granted a marketing authorization for Supemtek, a quadrivalent (four-strain) recombinant influenza vaccine, for the prevention of influenza in adults aged 18 years and older.
- 09 Sep 2017 Results published in the Journal of Infectious Diseases.
- 26 Oct 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.